
APPENDIX 15: CLINICAL FOREST PLOTS

1.1 P	sychosocial interventions	
1.1.1	Behavioural therapies aimed at communication	1
1.1.2	Behavioural therapies aimed at behaviour management	1
1.1.3	Cognitive behavioural therapies	2
1.1.4	Leisure programmes	
1.1.5	Social learning interventions	
1.1.6	Supported employment programmes	
1.1.7	Support for families and carers	
1.2 B	iomedical interventions	8
1.2.1	Antipsychotics	8
1.2.2	Anticonvulsants	
1.2.3	Drugs affecting cognition	16
1.2.4	Adrenocorticotrophic hormones	
1.2.5	Secretin	
1.2.6	Stimulants	
1.2.7	Antidepressants	20
1.2.8	Restrictive diets, vitamins, minerals and supplements	22
1.3 S	ettings for care	25
1.3.1		
1.3.2	Residential accommodation and related services	

1.1 PSYCHOSOCIAL INTERVENTIONS


1.1.1 Behavioural therapies aimed at communication

1.1.1.1 Natural language teaching compared with analog language teaching for communication in adults with autism




1.1.2 Behavioural therapies aimed at behaviour management

1.1.2.1 Independence training versus no treatment control for activities of daily living (showering) in adults with intellectual disability




1.1.2.2 Behavioural weight control programme versus no treatment control for self care (weight loss) in adults with intellectual disability




1.1.3 Cognitive behavioural therapies


1.1.3.1 Cognitive behavioural therapy versus treatment as usual for severity of coexisting OCD symptoms in adults with autism




1.1.3.2 Anti-victimization skills training versus waitlist control for anti-victimization skills (continuous measure) in adults with intellectual disability



1.1.3.3 Anti-victimization skills training versus waitlist control for anti-victimization skills (dichotomous measure) in adults with intellectual disability




1.1.3.4 Anger management versus waitlist control or treatment as usual for anger in adults with intellectual disability




1.1.4 Leisure programmes

1.1.4.1 Leisure programme compared with waitlist control for quality of life in adults with autism




1.1.4.2 Leisure programme compared with waitlist control for emotion recognition in adults with autism




1.1.5 Social learning interventions


1.1.5.1 Emotion recognition training compared with treatment as usual for emotion recognition in adults with autism



1.1.5.2 Social skills group compared with waitlist control for social interaction in adolescents with autism




1.1.5.3 Social skills group compared with treatment as usual for maladaptive behaviour in adults with intellectual disability




1.1.6 Supported employment programmes


1.1.6.1 Supported employment compared with sheltered workshop for autistic behaviours in adults with autism




1.1.6.2 Supported employment compared with sheltered workshop for quality of life in adults with autism



1.1.6.3 Supported employment compared with waitlist control for executive function in adults with autism




1.1.6.4 Supported employment compared with treatment-as-usual control for job placements in adults with autism




1.1.7 Support for families and carers


1.1.7.1 Psychoeducational group permanency planning intervention compared with treatment as usual for knowledge and awareness about planning in mothers of adults with intellectual disability




1.1.7.2 Psychoeducational group permanency planning intervention compared with treatment as usual for competence and confidence to plan in mothers of adults with intellectual disability



1.1.7.3 Psychoeducational group permanency planning intervention compared with treatment as usual for appraisals of the planning process by mothers of adults with intellectual disability



1.1.7.4 Psychoeducational group permanency planning intervention compared with treatment as usual for intermediate planning behaviours of mothers of adults with intellectual disability



1.1.7.5 Psychoeducational group permanency planning intervention compared with treatment as usual for residential and legal planning of mothers of adults with intellectual disability

		E	Experimental	Control		Std. Mean Difference		Std. Mean Difference				
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% C	CI	IV, F	ixed, 9	5% CI		
BOTSFORD2004	-1.0154	0.409201	13	14	100.0%	-1.02 [-1.82, -0.21]]	-				
Total (95% CI)			13	14	100.0%	-1.02 [-1.82, -0.21]		<	▶			
Heterogeneity: Not ap Test for overall effect:	•						-4 Favours 6	-2 experimer	0 ntal Fa	2 avours co	4	


1.2 BIOMEDICAL INTERVENTIONS

1.2.1 Antipsychotics


1.2.1.1 Risperidone compared with placebo for challenging behaviour (irritability & aggression) in adults with autism

		1	Experimental	Control		Std. Mean Differen					
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% CI		IV, F	xed, 9	5% CI	
HELLINGS2006	-0.64	0.34949	18	17	54.1%	-0.64 [-1.32, 0.04]		_			
MCDOUGLE1998	-0.96168	0.379583	15	16	45.9%	-0.96 [-1.71, -0.22]		-	\vdash		
Total (95% CI)			33	33	100.0%	-0.79 [-1.29, -0.28]		•			
Heterogeneity: Chi ² = Test for overall effect:	0.39, df = 1 (P = 0.53); I^2 Z = 3.06 (P = 0.002)	= 0%				_	-4	-2	0_	2	4
1001101010101	2 - 0.00 (0.002)					Fa	vours ex	kperiment	al Fa	vours co	ntrol


1.2.1.2 Risperidone compared with placebo for autistic core symptoms (repetitive behaviour) in adults with autism




1.2.1.3 Risperidone compared with placebo for autistic behaviours in adults with autism




1.2.1.4 Risperidone compared with placebo for symptom severity/improvement in adults with autism




1.2.1.5 Risperidone compared with placebo for challenging behaviour in adults with intellectual disability




1.2.1.6 Risperidone compared with placebo for aggression in adults with intellectual disability




1.2.1.7 Risperidone compared with placebo for symptom severity/improvement in adults with intellectual disability




1.2.1.8 Risperidone compared with placebo for quality of life in adults with intellectual disability




1.2.1.9 Haloperidol compared with placebo for autistic behaviours in adolescents with autism




1.2.1.10 Haloperidol compared with placebo for side effects (global) in adolescents with autism




1.2.1.11 Haloperidol compared with placebo for challenging behaviour in adults with intellectual disability




1.2.1.12 Haloperidol compared with placebo for aggression in adults with intellectual disability




1.2.1.13 Haloperidol compared with placebo for symptom severity/improvement in adults with intellectual disability




1.2.1.14 Haloperidol compared with placebo for quality of life in adults with intellectual disability




1.2.1.15 Risperidone compared with haloperidol for challenging behaviour in adults with intellectual disability




1.2.1.16 Risperidone compared with haloperidol for aggression in adults with intellectual disability




1.2.1.17 Risperidone compared with haloperidol for symptom severity/improvement in adults with intellectual disability




1.2.1.18 Risperidone compared with haloperidol for quality of life in adults with intellectual disability




1.2.1.19 Zuclopenthixol compared with placebo for challenging behaviour (aggression; endpoint data) in adults with intellectual disability




1.2.1.20 Zuclopenthixol compared with placebo for challenging behaviour (irritability; change from baseline data) in adults with intellectual disability




1.2.1.21 Zuclopenthixol compared with placebo for symptom severity/improvement (endpoint data) in adults with intellectual disability




1.2.1.22 Zuclopenthixol compared with placebo for symptom severity/improvement (change from baseline data) in adults with intellectual disability



1.2.1.23 Prothipendyl compared with placebo for symptom severity/improvement in adults with intellectual disability



1.2.1.24 Cis(z)-clopenthixol compared with haloperidol for symptom severity/improvement in adults with intellectual disability



1.2.1.25 Cis(z)-clopenthixol compared with haloperidol for side effects in adults with intellectual disability



1.2.2 Anticonvulsants


1.2.2.1 Valproate compared with placebo for challenging behaviour (irritability; continuous data) in children with autism

	Experimental			Control				Std. Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	CI	IV, F	ixed, 9	5% CI	
HELLINGS2005	18.17	8.79	16	15.45	10.39	14	53.8%	0.28 [-0.44, 1.00]	l			_	
HOLLANDER2010	14.5	6.67	16	17.7	7.94	11	46.2%	-0.43 [-1.21, 0.35]	l	-	-		
Total (95% CI)			32			25	100.0%	-0.05 [-0.58, 0.48]			•		
Heterogeneity: Chi ² = 1.71, df = 1 (P = 0.19); I^2 = 41%									-4	-2	_	2	4
Test for overall effect: $Z = 0.19$ (P = 0.85)									Favours ex	_	ıtal Fa	vours co	-


1.2.2.2 Valproate compared with placebo for challenging behaviour (irritability; dichotomous data) in children with autism




1.2.2.3 Valproate compared with placebo for challenging behaviour (aggression) in children with autism



1.2.2.4 Valproate compared with placebo for symptom severity/improvement in children with autism




1.2.2.5 Valproate compared with placebo for side effects in children with autism




1.2.3 Drugs affecting cognition

1.2.3.1 Donepezil hydrochloride compared with placebo for autistic behaviours in children with autism




1.2.3.2 Amantadine hydrochloride compared with placebo for challenging behaviour (irritability) in children with autism




1.2.4 Adrenocorticotrophic hormones


1.2.4.1 ORG 2766 compared with placebo for challenging behaviour (social withdrawal) in children with autism



1.2.4.2 ORG 2766 compared with placebo for challenging behaviour (social isolation) in children with autism




1.2.4.3 ORG 2766 compared with placebo for symptom severity/improvement in children with autism



1.2.5 Secretin


1.2.5.1 Secretin compared with placebo for core autistic symptoms of communication and symbolic behaviour in children with autism



1.2.5.2 Secretin compared with placebo for autistic behaviours in children with autism


		1	Experimental	Control			Std. Mean Difference				
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% C	1	IV, I	Fixed, 95	% CI	
CHEZ2000	-0.15	0.408163	12	12	28.1%	-0.15 [-0.95, 0.65]			-		
LEVY2003	-0.28055	0.255247	31	31	71.9%	-0.28 [-0.78, 0.22]			+		
Total (95% CI)			43	43	100.0%	-0.24 [-0.67, 0.18]			•		
Heterogeneity: Chi ² = Test for overall effect:	0.07, df = 1 (P = 0.79); l ² Z = 1.13 (P = 0.26)	= 0%				F	-4 avours e	-2 xperime	0 ntal Fav	2 /ours co	4 ntrol

1.2.5.3 Secretin compared with placebo for challenging behaviour in children with autism




1.2.6 Stimulants


1.2.6.1 Methylphenidate compared with placebo for coexisting hyperactivity in children with autism



1.2.6.2 Methylphenidate compared with placebo for the core autistic symptom of social interaction in children with autism




1.2.6.3 Methylphenidate compared with placebo for the core autistic symptom of repetitive behaviour in children with autism




1.2.7 Antidepressants


1.2.7.1 Clomipramine compared with placebo for autistic behaviours in adolescents with autism




1.2.7.2 Clomipramine compared with placebo for global side effects in adolescents with autism




1.2.7.3 Fluvoxamine compared with placebo for the core autistic symptom of repetitive behaviour in adults with autism



1.2.7.4 Fluvoxamine compared with placebo for autistic behaviours in adults with autism




1.2.7.5 Fluvoxamine compared with placebo for the challenging behaviour of aggression (change-from-baseline scores) in adults with autism




1.2.7.6 Fluvoxamine compared with placebo for maladaptive behaviour (change-frombaseline scores) in adults with autism

		1	Experimental	Control		Std. Mean Difference		Std. Mean Difference				
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% CI		IV, F	ixed, 9	95% CI		
MCDOUGLE1996	-1.61121	0.420238	15	15	100.0%	-1.61 [-2.43, -0.79]		-	-			
Total (95% CI)			15	15	100.0%	-1.61 [-2.43, -0.79]		•	-			
Heterogeneity: Not ap	plicable					•	-			+		
Test for overall effect:	Z = 3.83 (P = 0.0001)					Fa	-4 vours e	-2 xperimer	ntal F	avours c	4 ontrol	

1.2.7.7 Fluvoxamine compared with placebo for symptom severity/improvement (dichotomous measure) in adults with autism




1.2.7.8 Fluvoxamine compared with placebo for symptom severity/improvement (continuous measure) in adults with autism




1.2.8 Restrictive diets, vitamins, minerals and supplements


1.2.8.1 Gluten-and-casein-free diet compared with treatment as usual for autistic behaviours (social isolation and bizarre behaviour) in children with autism




1.2.8.2 Digestive enzyme supplementation compared with placebo for core autistic symptoms (communication) in children with autism




1.2.8.3 Digestive enzyme supplementation compared with placebo for challenging behaviour in children with autism




1.2.8.4 Digestive enzyme supplementation compared with placebo for gastrointestinal symptoms in children with autism




1.2.8.5 L-carnosine compared with placebo for autistic behaviours in children with autism




1.2.8.6 L-carnosine compared with placebo for symptom severity/improvement in children with autism




1.2.8.7 Micronutrient compared with standard medication for autistic behaviours in children with autism



1.2.8.8 Micronutrient compared with standard medication for challenging behaviour (irritability) in children with autism




1.2.8.9 Micronutrient compared with standard medication for symptom severity/improvement in children with autism



1.3 SETTINGS FOR CARE


1.3.1 Community based teams

1.3.1.1 Current living compared with developmental centre group home training environments for teaching community living skills to adults with intellectual disability




1.3.2 Residential accommodation and related services


1.3.2.1 Residential institution compared with community housing for adaptive behaviour in adults with intellectual disability



1.3.2.2 Residential institution compared with community housing for residential satisfaction (total score) in adults with intellectual disability




1.3.2.3 Residential institution compared with community housing for residential satisfaction with social life in adults with intellectual disability




1.3.2.4 Residential institution compared with community housing for residential satisfaction with autonomy in adults with intellectual disability

	Residenti	ial instit	uion	Con	Community			Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	<u> </u>	IV, I	Fixed, 95	% CI	
BARLOW1991	13.9	1.1	14	15.1	1.8	15	100.0%	-1.20 [-2.28, -0.12]					
Total (95% CI)			14			15	100.0%	-1.20 [-2.28, -0.12]			•		
Heterogeneity: Not app Test for overall effect: 2		= 0.03)							-20 Favo	-10 urs commu	0 nity Fav	10 rours institu	20 ution


1.3.2.5 Residential institution compared with community housing for social skills in adults with intellectual disability




1.3.2.6 Residential institution compared with community housing for social inclusion of adults with intellectual disability




1.3.2.7 Residential institution compared with community housing for social inclusion of adults with intellectual disability




1.3.2.8 Residential institution compared with community housing for quality of life of adults with intellectual disability




1.3.2.9 Small residential homes compared with institution for quality of life of adults with intellectual disability




1.3.2.10 Small residential homes compared with institution for choice making of adults with intellectual disability



1.3.2.11 Small residential homes compared with institution for community inclusion of adults with intellectual disability




1.3.2.12 Small residential homes compared with institution for family contact of adults with intellectual disability




1.3.2.13 Dispersed supported housing compared with residential group home for social inclusion of adults with intellectual disability

	Disperse	d suppo	rted	Reside	ntial hoi	mes		Mean Difference	Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixe	ed, 95% CI			
MCCONKEY2007	5.7	1.8	103	4.8	1.9	138	100.0%	0.90 [0.43, 1.37]						
Total (95% CI)			103			138	100.0%	0.90 [0.43, 1.37]	1		*	1		
Heterogeneity: Not app Test for overall effect:		0.0002)							-10 dential homes	0 Favours disp	10 persed sup	20 port	

1.3.2.14 Group homes compared with semi-independent apartments for resident satisfaction of adults with intellectual disability



1.3.2.15 Placement into a transitional developmental centre before placement into intermediate care facilities versus direct placement into intermediate care facilities for adaptive behaviour of adults with intellectual disability



1.3.2.16 Person-centred compared with system-centred planning for movement into the community of adults with intellectual disability

	Experim	ental	Contr	ol lo		Risk Ratio	Risk Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, F	ixed, 9	95% CI	<u> </u>	
HOLBURN2004	18	19	5	18	100.0%	3.41 [1.61, 7.24]			-			
Total (95% CI)		19		18	100.0%	3.41 [1.61, 7.24]			- -	•		
Total events	18		5									
Heterogeneity: Not app	olicable						0.01	0.1	+	 		100
Test for overall effect:	Z = 3.20 (P)	r = 0.001	1)					vours contr	ol Fa		-	